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Letters to the Editor 
Ann Arbor, MI, May 23, 1985 
Dear Editor, 
We are writing with regard to the article by Dionne et al. [3], which is entitled 
‘Contrast Medium Cause the Apparent Increase in Beta-Endorphin Levels in 
Human CSF Following Brain Stimulation.’ 
The main conclusion of the article is derived from the observation that more 
beta-endorphin immunoreactivity is read following the injection of the contrast 
medium. The authors, therefore attribute the brain stimulation-induced elevation in 
endorphins which we have reported [l] to an artifact of the contrast medium on the 
assay. It is clear from their statement in the discussion that they assumed that our 
baseline sample, to which post-stimulation values were compared, preceded the 
injection of the contrast medium. In fact, however, our baseline samples were 
obtained after the dye was injected and after the electrode was implanted. In other 
words, what we called baseline is equivalent to their sample no. 3. Upon re-reading 
our original description, it is apparent that we may not have been sufficiently precise 
in our definition of baseline. We simply stated ‘the first sample was obtained prior 
to the electrical stimulation and constituted the baseline control.’ We did not specify 
that the sample contained the contrast medium. We do apologize for this omission; 
we must add, however, that our definition of baseline appeared to be the only 
experimentally sound one, as amply demonstrated by the Dionne et al. finding. So to 
clarify - in all our subjects the Conray dye was injected first and an X-ray 
obtained. The electrode was lowered to the target and another X-ray was obtained. 
The neurological status of the patient and his pain responsiveness was tested. One 
ml of CSF was withdrawn and discarded, to wash the dye off the walls of the 
cannula. Then the baseline sample was collected. This was immediately followed by 
electrical stimulation and collection of post-stimulation samples as described [l]. 
Thus, injection of the dye cannot explain our finding of elevated opioid levels upon 
stimulation. 
Given that our baseline sample did contain the contrast medium, it should be 
noted here that under our assay conditions we read very low levels of beta-en- 
dorphin at baseline. Why should the dye not affect our radioimmunoassay? We 
believe it is a matter of dye concentration in the tube. We have used 100 ~1 of 
CSF/tube, whereas Dionne et al. used the equivalent of 850 ~1. Thus we would be 
adding 8-9-fold less dye, and everything else being equal, we would get a great deal 
less interference. Further, the authors appear to have obtained the CSF very shortly 
post-dye, whereas in our case over an hour elapsed before we obtained the baseline. 
It should also be noted that in the Science report [2], which the authors discuss, 
the CSRsamples were first purified using 2 different techniques (biobead absorption 
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and ion exchange) prior to assay. One of the assays for opioid .tctivity was a 
bioassay (vas deferens) and the C‘SF opioid effects were reversed l-v naloxnne. This 
latter criterion would preclude non-specific dye effects. 
In sum, our baseline measurement was post-dye. post-electrode implant and was 
separated from the other samples only by the actual brain stimulation. Thus, while 
we acknowledge the potential non-specific effects of the contrast medium, the 
elevations in opioids we have observed. using either radioimmunoassay or radiore- 
ceptor and bioassay. cannot be due to that artifact. 
We feel that the Dionne et al. paper [3] does attract attention to an important 
potential problem especially when the CSF is concentrated prior to assay. The 
question remains. why did we observe post-stimulation elevations in endorphins and 
they did not (even on day 2 when no dye was present in the samples). The variability 
among reports is likely to be due to variation in the specific site of the implant. 
While we do not maintain that endorphin release is either necessary or sufficient to 
the production of stimulation-produced analgesia, we believe, based on our con- 
tinued experience to date, that they are often correlated. Hopefully, future studies 
using newer and better purification techniques of the peptides will clarify the actual 
relationship between particular endogenous opioids and the production of analgesia. 
Mental Health Research Institute. 
University of Michigan, 
Ann Arbor, MI 48109 (U.S.A.) 
HUDA AKIL 
DONALD E. RICHARDSON 
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